Beardsley: In the panel discussion this afternoon, you asked a representative of the National Science Foundation [NSF] how, given that environmental genomics is a multidisciplinary field, the foundation plans to encourage researchers who do not have the needed biological, genomics, and computational skills to use the new tools becoming available. What's your own answer?
Venter: It's something the funding agencies have to do. You heard the answer [given by Maryanna Henkart, director of NSF's Division of Molecular and Cellular Bioscience]: "Money helps." That's the standard NSF answer, but money is just part of it: The NSF views the people it funds as clients, a constituency. There are certain stages of rapid transformation in our approaches to scientific information that mean there has to be leadership. There will eventually be adjustments and new equilibriums. But when there is fundamentally new information that potentially changes what scientists do, when you take into account the changing nature of the experiments and so forth, I think the agencies have an obligation to push and to lead, not just to go with the flow.
Progress has been pretty impressive thus far. You heard from the other funding groups. We're fortunate to have the support of the Sloan Foundation, the Gordon and Betty Moore Foundation, and equally the Department of Energy. All three have been out in front. I think the obligation should extend to the National Institutes of Health and the NSF, because what I am trying to tell people is that our data show we are enveloped in a spectrum of biology.
Humans like to think they are separate from this. Howard Hughes tried to live in a sterile environment, with tissue boxes on his feet. That's maybe an extreme example. But how many advertisements do we see on TV in which people try to sterilize their environment? Maybe we should launch a range of consumer products, because people will learn that we all breathe in billions of bacteria, fungi, and viruses every day. Just because we can't see them doesn't mean they don't exist. We're in a continuum of biology and microbiology. The estimates are that we have at least as many microorganism cells in our body as our own hundred trillion cells. If we were sterile and lived in a sterile environment, we would be in deep trouble. So our work is presenting a very different view of ecology, the environment, and ecosystems, and showing us the broad spectrum of life. By concentrating on just a few organisms isolated from the environment, we've been living with a false notion.
Beardsley: You don't think National Institutes of Health and the NSF have been leading as much as the other organizations you mentioned?
Venter: No, I don't think they have been leading. I think they need to do much more leading and less following of the consensus. If you rely on the consensus of the people you're funding, it makes it a lot more difficult to move to the next stage. You have to wait until the average catches up with the forefront to enable that.
Beardsley: At this conference, I've been impressed by the new emphasis on the environment. Is that going to continue in future years, or is this a one-off?
Venter: I think it's one of the biggest expanding areas. It's showing the global aspects of genomics, which is not just the human genome. As Ari Patrinos [then associate director for biological and environmental research at the US Department of Energy] said, everything from potential climate change to understanding the complexities of the carbon cycle is affected. As new databases and tools become available, this will be an area of expanded emphasis. I've set the agenda for the past 17 years for this conference, and I've tried to select things that were of significance to me and of significance to the fields. I've always tried to do it in a forward-looking fashion.
All the areas discussed here are pretty new and hot. They're "bleeding edge," not just leading edge. That creates a challenge, because some of the talks were short on data and long on philosophy and direction. But in the early years, groups were talking about how they would sequence the human genome. It rapidly got to the point where we're analyzing it. The same will be true for whole ecosystems. Venter: No, I'm trying to challenge the whole scientific community to do it. The resources are there. Ari Patrinos's plea that biologists need to wake up and get together to develop the needed computing resources is valid. That's critical. It's why we're making changes to the sequencing prize [a prize of $500,000 offered by Venter's foundation to the first group that can sequence a human genome for $1000]. We're constantly trying to prod and lead the community with new challenges, to move it forward faster. We're moving the prize from my foundation, which was to provide a halfmillion dollar prize, to the X-Prize Foundation, where I am on the board. And we are trying to increase the prize amount 10-or 20-fold, to $5 million or $10 million. But we are going to put in place strict criteria. We won't just take someone's word for it that they can sequence a genome for $1000. They'll have to demonstrate it by sequencing a hundred human genomes.
Beardsley

Beardsley: There's a lot of talk at this conference about 454 Life Sciences' new sequencing technology. Could that be the way the prize will be gained?
Venter: There were several groups in the last session, all companies, presenting a variety of different views and approaches and technological achievements. It was pretty exciting. Any one of them I feel has the potential to get there, and hopefully, if there's a $5 million to $10 million prize, it might motivate some new people to try. That's the point of this type of prize. It's to encourage and prod and stimulate people to do things that they might not ordinarily do, to see if we can get there faster.
Beardsley: This is in addition to the Marine Microbe Sequencing Project, in which you aim to sequence more than 150 microbes?
Venter: Yes, the Moore Foundation is supporting that initiative. We first called it the Moore 130. It's now the Moore 155 or the Moore 160. It shows the extraordinary change in this field. Ten years ago, we took a microbial sequencing project from a 10-plus-year project-sequencing yeast took 10 years and a thousand scientists, 10 years ago-to a four-month project. Now institutions like mine can sequence literally hundreds of genomes a year, using a fraction of our facility. And if these new technologies come on, it'll be tens or hundreds of genomes a day, or a week. That's feasible. There are only 5000 microbial species now known, including all pathogens, and only five environmentally important organisms have been sequenced. We sequenced those with Energy Department funding. Now we're going from 5 to 155 in one year.
Beardsley: Do you see this as a pure science endeavor, or do you have applications in mind, for example, environmental challenges and energy supply challenges? Microbes play an important part in global geochemistry. Is concern about environmental changes part of your motivation?
Venter: Absolutely. You're right. What I'm hoping will happen is that out of this basic science, information will come that prompts new science and stimulates new ideas. Hopefully, breakthroughs will lead to solutions to some of the problems. But I believe firmly that that only happens with strong basic science. When I sequenced the human genome, even though I had to do it in a company because we couldn't get federal funding, that was the largest basic science experiment ever done.
Beardsley: Aren't many of the talks here focusing more on microbial diversity than on basic energy research?
Venter: That's an extension of your last question. We're hoping to stimulate some new types of research. We might have sessions at future conferences on carbonbased fuels that might be alternatives to oil and coal. I think the science needs to progress a little bit further before we can have major sessions on that. Right now we're dealing with the basic science phase, and hoping that that will drive the thinking in other areas. We have teams doing work in those areas. If we had achieved a breakthrough, you can be relatively confident we'd be announcing it. We certainly wouldn't be keeping it a secret. Venter: Yes, we'll be finishing our first circumnavigation then.
Beardsley:
And what happens then? I can't believe you're going to just come ashore.
Venter: Oh no. That's the first circumnavigation. I think what we've already learned about diversity was stunning to everybody. The questions were put up on a slide yesterday. Is everything everywhere? We know the answer to that already. The answer is "no."
Are there region-specific and environment-specific organisms? Not only is the answer "yes," but the answer is "yes, every 200 miles in the ocean."Which is pretty amazing. So everything is not everywhere, and maybe the ocean includes a million, or 10 million, microenvironments that are totally unique. We don't know yet. The Sorcerer expedition dealt with only the first couple of meters of depth of the water: That's why we find so many new photoreceptors. And we followed a narrow path near the equator. We haven't touched the extremes of depth, although people have shown there are different sets of microorganisms at every depth in the ocean. Ari [Patrinos] asked some of the important questions: How reproducible is this result? Are the microenvironments dynamically changing, or are they stable? When you realize that the paradigm that I developed works-that you can take a small sample from an environment and shotgun sequence it-it doesn't take a lot of brilliance to think of hundreds or thousands of different environments and experiments that you'd like do that for. We want to describe the extent of diversity. I would like to explore that discovery until the curve [of cumulative new sequences as a function of microenvironments] starts to level off, showing that we are approaching saturation. Because until then we don't have a grasp of biology on our own planet. We might do that with helicopters, airplanes, submarines, sailboats, or all of the above.
Beardsley: Shouldn't the NSF have a ship doing this?
Venter: The NSF funded us to do a trial experiment. And we're grateful that they did. But our government science system is great at funding the expansion of something once the fundamental answer is known: Does the experiment work? It's virtually impossible to get funding from the US government to test a new idea. Without private foundations, progress would be slow. My foundation has funded a lot of this, and so has the Gordon and Betty Moore Foundation. We'd been trying for a long time to try to get money for the air genome project [a project to sequence microbes found in air]. The Sloan Foundation came up with funding for that. But after we publish our data on the air genome project, I guarantee that we'll be able to get government support. It's the nature of the beast. The study section and the peerreview process draw things down toward the mean, away from the unique.
Beardsley: On the cancer side, your former colleague William A. Haseltine (one-time chairman and chief executive officer of Human Genome Sciences, Inc.) was dead set against the idea of personalizing cancer medicine on the basis of an individual's genome. He didn't think that could be economically viable. Do you think otherwise?
Venter: People who sell things don't like that notion. It's an economic gamble for nations and for individuals. We have to find a way to lower health care costs. Preventative medicine is the only way I can think of to do that rationally. So trying to prevent disease, trying to get people early tests and early diagnosis, is the opposite strategy from that of people who want to come in with a brilliant billion-dollar Plenary speakers and discussion groups will approach that topic from several interwoven perspectives. In recent years, policymakers have increasingly recognized the economic values associated with biodiversity, economists have increasingly found ways to incorporate values associated with biodiversity into economic thinking, and scientists have increasingly documented the variety of services that diverse ecosystems provide. Participants will have the opportunity to explore the many and diverse linkages among these fields.
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drug to treat diseases. Understanding the human genome gives us the opportunity to understand susceptibility to disease and do something about it early on. Look at the paper that [Robert L.] Strausberg and his team just published about somatic changes in tyrosine kinase receptors in glioblastomas [Proceedings of the National Academy of Sciences 102: 14344-14349]. The original prototype for a tyrosine kinase receptor inhibitor is Gleevec. Marv Frazier, our vice president for science at the institute, is one of the original Gleevec miracle survivors. We're trying to find changes in the genome that are caused by the environment, changes from radiation, changes from toxins. Because only about 3 to 5 percent of cancer is inherited. The rest is environmentally caused. These discoveries can help patients quickly. If someone was developing new drugs for cancer that inhibited tyrosine kinase receptors, they would not be able to get anything through clinical trials without knowing the sequences of the targeted receptors and which ones are mutated, because that will determine which drugs you use to treat which patients. So not only is understanding the changes critical for preventing disease, it will be critical for determining the right therapy for the right patient. It's important to stress that these are somatic changes, not inherited genetic changes. Venter: Yes, they're totally available. We're considering, in fact, whether to digitize all of them and make them available online. The history of science is important, and this field is developing over a short period of time. We also have material on the early work on the structure of DNA: Rosalind Franklin's key papers, her photo 51 [the key DNA X-ray diffraction image that pointed to the double helix], the actual flask that she crystallized DNA in (with some DNA in it), the first draft of [James D.] Watsons's The Double Helix with [Maurice] Wilkins' marginal notes about all the things he thought were wrong with it. When you add to that Ham Smith's work on the first restriction enzymes, and then the work Ham and I did together for sequencing the first genome, the collection covers the period from before the structure of DNA was known to the sequencing of the human genome. Maybe it will include the first synthetic genomes. We definitely wanted to make sure that collection will stay together and that it does not end up in private homes. It's available now to scholars.
Beardsley: Are you happy with the received wisdom that you will go down in history as the man who got joint first prize in the race to sequence the human genome, or are you unhappy with that story?
Venter: The competition to sequence the human genome brought genomic science to the lay public and so is seen in that context. It was the work that I did before sequencing the human genome that made sequencing the human genome possible, by me or anybody else. And it's that work that's led to what we're doing in the environment. So I think that was important science, and it's the most widely known public science. But I hope I can follow in the shoes of Ham Smith and have some of my best science happening in my 60s and 70s and 80s.
Beardsley: And that's going to have a strong environmental component?
Venter: Absolutely. Not too many scientists have the freedom to work broadly on what they think is important. The environment relates directly to human health, as we've shown in cancer. It's the environmental toxins, the environmental changes, that are causing the genetic changes in cancer. So by providing an understanding of those changes, this work can lead to new treatments for cancer. It's all related.
